Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19231488 | 0.82 | — | — | |
| SCHEMBL10072896 | 0.82 | — | — | |
| SCHEMBL14638747 | 0.78 | NPSR1 (0.38) | — | |
| SCHEMBL21738681 | 0.78 | — | — | |
| SCHEMBL18653337 | 0.78 | — | — | |
| SCHEMBL23366120 | 0.78 | — | — | |
| SCHEMBL10073174 | 0.74 | ALDH1A1 (0.33) | — | |
| SCHEMBL17662468 | 0.74 | TSHR (0.32) | — | |
| SCHEMBL18087338 | 0.74 | CYP2C19 (0.33) | CYP2C19 | |
| SCHEMBL16670401 | 0.72 | SMN1; SMN2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240342295-A1 | FUNCTIONALISATION OF CARBOXYMETHYLCELLULOSE | THE UNIVERSITY OF MANCHESTER (GB) | 2024-10-17 | — | — | US | disclosed |
| EP-4377363-A1 | FUNCTIONALISATION OF CARBOXYMETHYLCELLULOSE | The University of Manchester (GB) | 2024-06-05 | — | — | EP | disclosed |
| US-20240041982-A1 | EXTENDED RELEASE HYDROGEL CONJUGATES OF C-NATRIURETIC PEPTIDES | PROLYNX LLC (US) | 2024-02-08 | — | — | US | disclosed |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | NOVARTIS AG (CH) | 2023-09-12 | — | — | US | disclosed |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | NOVARTIS AG (CH) | 2023-09-12 | — | — | US | disclosed |
| WO-2023006909-A1 | FUNCTIONALISATION OF CARBOXYMETHYLCELLULOSE | THE UNIVERSITY OF MANCHESTER (GB) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023006909-A1 | FUNCTIONALISATION OF CARBOXYMETHYLCELLULOSE | THE UNIVERSITY OF MANCHESTER (GB) | 2023-02-02 | — | — | WO | disclosed |
| EP-3988170-A1 | FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | Novartis AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| US-20210000964-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20180214561-A1 | EIGHT-ARM POLYETHYLENE GLYCOL DERIVATIVE, PRODUCTION METHOD THEREFOR, AND MODIFIEDBIO-RELATEDSUBSTANCETHEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2018-08-02 | — | — | US | disclosed |
| US-8709382-B2 | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules | IMMUNOMEDICS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20140017168-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140017168-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8545809-B2 | Methods and compositions for improved 18F labeling of proteins, peptides and other molecules | IMMUNOMEDICS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8545809-B2 | Methods and compositions for improved 18F labeling of proteins, peptides and other molecules | IMMUNOMEDICS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| WO-2013132268-A1 | CHEMICAL MODIFICATION OF ANTIBODIES | UCL BUSINESS PLC (GB) | 2013-09-12 | — | — | WO | disclosed |
| WO-2012082618-A2 | METHODS AND COMPOSITIONS FOR IMPROVED F-18 LABELING OF PROTEINS, PEPTIDES AND OTHER MOLECULES | IMMUNOMEDICS, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120134920-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2012057624-A1 | NOVEL BICYCLIC PEPTIDE MIMETICS | PEPSCAN SYSTEMS B.V. (NL) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012057624-A1 | NOVEL BICYCLIC PEPTIDE MIMETICS | PEPSCAN SYSTEMS B.V. (NL) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214561-A1 | EIGHT-ARM POLYETHYLENE GLYCOL DERIVATIVE, PRODUCTION METHOD THEREFOR, AND MODIFIEDBIO-RELATEDSUBSTANCETHEREOF | MRPL38, CXCL8, ALG8 | CYP2C19 2853/4885 |
| US-20240041982-A1 | EXTENDED RELEASE HYDROGEL CONJUGATES OF C-NATRIURETIC PEPTIDES | NPPA, NPR1, NPR3 | CYP2C19 3676/4885 |
| US-20120134920-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | F13B, FCGRT, PAICS | CYP2C19 4081/4885 |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | FABP1, FABP2, FABP3 | CYP2C19 1162/4885 |
| US-20140017168-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | F13B, FCGRT, PAICS | CYP2C19 4081/4885 |
| US-20240342295-A1 | FUNCTIONALISATION OF CARBOXYMETHYLCELLULOSE | CHRM2, CMBL, H1-0 | CYP2C19 3141/4885 |
| US-20210000964-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | FABP1, FABP2, FABP3 | CYP2C19 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.